Our Founder and CEO, Dr. Jo Varshney, has been named to Inc.’s 2026 Female Founders 500. We couldn’t be prouder. Dr. Varshney founded VeriSIM Life on a conviction that the gap between animal experiments and human biology should no longer determine whether a medicine succeeds or fails. That conviction led her to build BIOiSIM®, our translational AI platform that helps pharma and biotech teams predict drug safety, efficacy, and dosing before a single patient enters a clinical trial. Inc. specifically recognized Dr. Varshney for validating the predictive accuracy of our AI-powered drug development platform and initiating health-system partnerships that are redefining how medicines reach patients. Under her leadership, VeriSIM Life has raised over $25M, built a robust therapeutic pipeline, and advanced our lead drug candidate toward its first human clinical studies. None of it happens without the team behind the science and technology, and none of it matters unless it gets better therapies to patients faster. That’s the mission. That’s what drives us. Congratulations, Dr. Varshney. #FemaleFounders500 #AIinDrugDevelopment #BIOiSIM #VeriSIMLife #WomenInAI #DrugDevelopment #BioTech #HealthTech
VeriSIM Life
Biotechnology Research
San Francisco, California 3,214 followers
Introducing BIOiSIM, an AI-driven drug development engine designed to de-risk and inform R&D decision-making.
About us
VeriSIM Life is building AI enabled biosimulation models. VeriSIM will tackle one of the biggest obstacles of drug development: animal testing for drug development. Animal testing is slow, ethically questionable, and doesn't act as much of a filter: 92% of all drug candidates that pass this preclinical testing never make it to market. VeriSIM's solution is to create disease-specific biosimulation models, which allow researchers at pharma companies to model in software how a drug will interact in animals. This will allow researchers to test 1000x more potential candidates in the same unit of time, ensuring that drugs that do make it to (human) clinical trials are far more likely to work, and therefore saving millions in annual costs.
- Website
-
http://verisimlife.com/
External link for VeriSIM Life
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- San Francisco, California
- Type
- Privately Held
- Founded
- 2017
Locations
-
Primary
Get directions
1 Sansome St
San Francisco, California 94104, US
Employees at VeriSIM Life
Updates
-
Subscribe to our newsletter to receive monthly updates on our work and the state of #AIinDrugDevelopment
-
At VeriSIM Life, our mission has always been to close the translational gap between preclinical research and successful clinical outcomes. As highlighted in a recent feature in the AJMC - The American Journal of Managed Care, integrating AI-driven data from multiple species, from rodents to humans, is transforming how preclinical studies are designed and interpreted. By harnessing advanced simulations that blend mechanistic biology with AI, we’re helping researchers choose better models, reduce unnecessary animal testing, derisk development, and get therapies to patients faster and more cost-effectively with our BIOiSIM platform. But this isn’t just about efficiency; it’s about improving predictive accuracy and reshaping expectations around how early-stage research informs human trials. 👉 Discussion question: If AI models rely on existing animal and human datasets to predict translational outcomes, how do we ensure that the insights AI generates don’t just reinforce inherent biases in those datasets and truly improve our ability to predict human responses? Article link in comments ⬇️
-
-
VeriSIM Life reposted this
I can not emphasize enough how much I agree with Dr. Samir Mitragotri! At VeriSIM Life, we believe drug failure is rarely about target selection alone. It is about #translation. Most discovery platforms stop at binding affinity or chemical optimization. We go further. We interrogate how a molecule behaves inside real human biological systems, how it distributes, how it is metabolized, how formulation alters exposure, and how delivery determines whether it ever reaches the tissue that matters. Derisking must happen before the clinic, not inside it. That means integrating mechanism, formulation science, pharmacology, and AI/computational modeling into one unified translational framework. Not just predicting if a drug should work, but whether it actually will. That distinction does not guarantee success, but it reduces avoidable failure before capital and patients are put at risk. #biotech #intergratedsystems #translationalsuccess
Professor @ Harvard University | Hiller Professor of Bioengineering | Hansjorg Wyss Professor of Biologically Inspired Engineering | Wyss Institute
Roughly 2,000 new molecules enter clinical testing worldwide each year. Yet the pace of drug discovery has not been matched by equivalent efforts in how they are delivered. Delivery technology is not merely an enabling tool; it can fundamentally determine therapeutic success. In many cases, an established molecule combined with an advanced delivery strategy can achieve greater efficacy, safety, and patient benefit than a newly discovered compound lacking such innovation. An exclusive focus on discovering new drugs, without comparable investment in unlocking the therapeutic potential of existing ones through delivery science, represents a missed opportunity. The consequences are substantial: unrealized health gains, avoidable development costs, and delayed societal benefit. Advancing drug delivery should be viewed not as incremental optimization, but as a central pillar of modern therapeutics. American Association of Pharmaceutical Scientists (AAPS) | @aapscomms, Controlled Release Society, Wyss Institute at Harvard University, AIChE - American Institute of Chemical Engineers, Biomedical Engineering Society National Academy of Engineering
-
At the 3DCC International Conference on Advances in 3D Cell Culture in Goa, Dr. Jo Varshney was proud to join a group of AI leaders who are moving beyond high-level conversations and into real implementation, especially in biologics. The dialogue was practical, technically grounded, and future-focused. One takeaway stood out: India is not simply adopting AI in life sciences. It is playing an active role in defining how the field evolves. 🌏🧬 At VeriSIM Life, we discussed how our BIOiSIM platform combines AI with mechanistic biology to improve translational prediction and reduce unnecessary reliance on animal testing, particularly for complex biologics. The conversation went into the realities of adoption, including how organizations build confidence in model outputs, how regulatory expectations are shaping development strategies, and why data rigor and biological relevance matter more than headline speed. Discussions like this reflect a broader shift across the industry. The focus is shifting from proof-of-concept AI to systems that support real decisions, align with regulatory frameworks, and deliver measurable impact on costs, timelines, and patient outcomes. Thank you to the 3DCC organizers for a thoughtful and well executed event! #AIinDrugDevelopment #Biologics
-
-
Subscribe to our newsletter to never miss an update! #DrugDevelopment #AIinDrugDevelopment #AIinDrugDiscovery
-
VeriSIM Life reposted this
The EPA’s announcement to phase out animal testing by 2035 is a clear signal that regulatory science is evolving toward human-relevant approaches. This is exactly why VeriSIM Life exists. Integrating mechanistic biology with AI enables more predictive, decision-shaping assessments before real-world exposure. This shift is no longer theoretical. It’s already being applied in regulatory and industrial programs. A meaningful step forward for environmental and chemical safety science. #TranslationalAI #HumanRelevantScience #RegulatoryScience #AlternativestoAnimalTesting
The EPA has announced its plans to phase-out animal testing completely by 2035. Thomas Hartung spoke to The New York Times on yesterday's announcement sharing his thoughts on what it means for alternative methods. He noted how AI in particular is supercharging the NAMs suite and aiding in the transition away from traditional mammal models. To read NYT's coverage of the announcement visit: https://lnkd.in/e88Df-Fu
-
VeriSIM Life reposted this
Hear from Dr. Jo Varshney, Founder & CEO of VeriSIM Life, as she shares what excites her most about joining #3DCC2026. Taking the stage as a speaker, Dr. Varshney will deliver a compelling talk titled “𝘈𝘐-𝘗𝘰𝘸𝘦𝘳𝘦𝘥 𝘛𝘳𝘢𝘯𝘴𝘭𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘔𝘰𝘥𝘦𝘭𝘴: 𝘈𝘤𝘤𝘦𝘭𝘦𝘳𝘢𝘵𝘪𝘯𝘨 𝘕𝘈𝘔𝘴 𝘧𝘰𝘳 𝘉𝘪𝘰𝘭𝘰𝘨𝘪𝘤𝘴 𝘢𝘯𝘥 𝘋𝘳𝘶𝘨 𝘋𝘦𝘷𝘦𝘭𝘰𝘱𝘮𝘦𝘯𝘵.” A pioneer in next-generation #digital platforms, she is redefining how #therapies move from concept to clinic—while championing #innovation, inclusion, and diversity in science. Join Dr. Jo Varshney at #3DCC2026 and explore how #AI is reshaping the future of #NAMs and drug development. Registrations CLOSING SOON: https://lnkd.in/d6dkgUwx 📅 Save the Date: January 22-23, 2026 📍Location: Novotel Dona Sylvia Resort, Goa For registration queries, reach out to us at, Neha Gupta: sales.executive@mumbaibiocluster.org Prajakta Dandekar Jain | Ratnesh Jain | Institute Of Chemical Technology | Mumbai Biocluster | Biologics Workshop #3DCC26 #BSW26 #Biologics2026 #3dcellculture #NAMs #AIML #digitaltwins #biologics #biotherapeutics #preclinical #organoids #spheroids #3dprinting #animaltesting #conferences #research #biopharma #preclinicalstudies #toxicology
-
VeriSIM Life reposted this
As #NAMs move from #innovation to industry standard, will AI/ML accelerate their true scale? Join us at #3DCC2026 for a high-impact discussion on “𝗔𝗱𝘃𝗮𝗻𝗰𝗲𝘀 𝗶𝗻 𝗔𝗜/𝗠𝗟 𝗳𝗼𝗿 𝟯𝗗 𝗖𝗲𝗹𝗹 𝗖𝘂𝗹𝘁𝘂𝗿𝗲 & 𝘁𝗵𝗲 𝗥𝗼𝗮𝗱 𝗔𝗵𝗲𝗮𝗱” where #global experts explore how #intelligent technologies are reshaping complex 𝘪𝘯-𝘷𝘪𝘵𝘳𝘰 models and accelerating drug development. Moderator: > Dr. Narendra Chirmule, CEO, SymphonyTech Biologics Esteemed Speakers & Panelists: > Dr. Jo Varshney, Founder & CEO, VeriSIM Life, Inc > Dr. Bikash Chatterjee, CSO, Pharmatech Associates, a USP company > Mr. Krishna Harsha Adusumilli, Business Solutions Manager, Aganitha Cognitive Solutions > Dr. Swadha Anand, Principal Scientist, Tata Consultancy Services Research The future of drug development starts here. #Biologicsx3DCC 2026 Registrations CLOSING SOON: https://lnkd.in/d6dkgUwx For registration queries, reach out to us at, Neha Gupta: sales.executive@mumbaibiocluster.org Prajakta Dandekar Jain | Ratnesh Jain | Institute Of Chemical Technology | Mumbai Biocluster | Biologics Workshop #3DCC26 #BSW26 #Biologics2026 #3dcellculture #NAMs #organoids #spheroids #AI #ML #digitaltwins #3dprinting #animaltesting #conferences #posterpresentation #research #biopharma #preclinicalstudies #toxicology
-
-
🔥 Final call for JPM Week and BIO Partnering meetings with Dr. Jo Varshney — only a few slots available. VeriSIM Life is enabling a shift from trial-and-error R&D to model-informed, explainable development. BIOiSIM® improves predictability, reduces unnecessary animal studies, and accelerates progress toward human outcomes. Ideal for teams looking to: • De-risk early decisions with mechanistic, AI-driven biosimulation 🤖 • Validate candidates with greater speed and confidence ⚡ • Strengthen investment and regulatory narratives with rigorous translational evidence 📈 • Explore platform-level or strategic partnerships 🤝 This window is closing quickly! Secure your time before the calendar fills. 👉 Reserve your meeting → https://lnkd.in/e6dnMqsU #JPM2025 #BIOPartnering #AIinBiotech #DrugDevelopment #LifeSciences #PredictiveModeling #BiotechLeadership
-